SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Orforglipron is a small molecule drug that targets the GLP-1R, with therapeutic applications in Nervous System Diseases.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Eplontersen, is an antisense oligonucleotide developed by Ionis Pharmaceuticals and Akcea Therapeutics.

Radella Pharmaceuticals reveals preliminary results from the Phase 1a trial of MD-18, a groundbreaking peptide aimed at PTP1B to combat obesity.

IWY-357 is a small molecule drug developed by Novartis AG, with a focus on the therapeutic area of infectious diseases.

TEZSPIRE achieved its two main goals in the Phase III WAYPOINT study involving patients with chronic rhinosinusitis and nasal polyps.

Basiliximab is a chimeric monoclonal antibody that targets the interleukin-2 receptor (IL-2R) alpha chain, also known as CD25.

Palleon Pharmaceuticals shares findings from the Phase 1/2 GLIMMER-01 study on E-602 combined with Cemiplimab for solid tumor patients at the SITC Annual Meeting.

Deutetrabenazine is a small molecule drug that targets VMAT2 and is used in the treatment of nervous system diseases, congenital disorders, and other diseases.